PMID- 12011125
OWN - NLM
STAT- MEDLINE
DCOM- 20020605
LR  - 20220316
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 20
IP  - 10
DP  - 2002 May 15
TI  - Comparison of cytogenetic and molecular cytogenetic detection of chromosome 
      abnormalities in 240 consecutive adult patients with acute myeloid leukemia.
PG  - 2480-5
AB  - PURPOSE: To prospectively compare cytogenetic and molecular cytogenetic analysis 
      for the detection of the most relevant chromosome abnormalities in a large series 
      of patients with acute myeloid leukemia (AML). PATIENTS AND METHODS: Two hundred 
      forty consecutive adult patients with AML entered onto the multicenter treatment 
      trial AML HD93 were studied. Chromosome banding and fluorescence in situ 
      hybridization (FISH) applying a comprehensive set of genomic DNA probes were 
      performed in a single reference laboratory. RESULTS: Two cases of inv(16), three 
      cases of t(11q23), and three cases of t(8;21)var were only detected by molecular 
      cytogenetics. By FISH, aberrations were identified in three cases with normal 
      karyotypes: inv(16), -Y (in a patient with low metaphase yield on chromosome 
      banding) and a 12p microdeletion. Additional aneuploidies, in particular +8q and 
      +11q, were diagnosed by FISH; however, virtually all these aberrations occurred 
      in patients with complex karyotypes or as an additional abnormality in leukemias 
      with an AML-specific translocation. Finally, aberrations were detected by FISH in 
      eight of 14 patients with no assessable metaphases. CONCLUSION: In most cases of 
      AML, conventional cytogenetic study reliably detects chromosomal abnormalities, 
      and this method should not be replaced by FISH. FISH should be used as a 
      complementary method for the detection of more subtle abnormalities, such as 
      inv(16) and t(11q23), in all patients with newly diagnosed AML and for suspected 
      t(8;21)var. Furthermore, molecular cytogenetics using this comprehensive set of 
      DNA probes provides a valuable diagnostic tool for patients with poor chromosome 
      morphology, low or no yields of metaphase cells, or both.
FAU - Frohling, Stefan
AU  - Frohling S
AD  - Department of Internal Medicine III, University Hospital of Ulm, 
      Robert-Koch-Strasse 8, 89081 Ulm, Germany.
FAU - Skelin, Silvia
AU  - Skelin S
FAU - Liebisch, Claudia
AU  - Liebisch C
FAU - Scholl, Claudia
AU  - Scholl C
FAU - Schlenk, Richard F
AU  - Schlenk RF
FAU - Dohner, Hartmut
AU  - Dohner H
FAU - Dohner, Konstanze
AU  - Dohner K
CN  - Acute Myeloid Leukemia Study Group, Ulm
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (DNA Probes)
RN  - 0 (DNA, Neoplasm)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - *Chromosome Aberrations
MH  - Chromosome Deletion
MH  - Chromosomes/*genetics
MH  - Cytogenetics
MH  - DNA Probes
MH  - DNA, Neoplasm/genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Karyotyping
MH  - Leukemia, Myeloid/*genetics/pathology
MH  - Middle Aged
MH  - Molecular Biology
MH  - Prospective Studies
MH  - Translocation, Genetic
EDAT- 2002/05/16 10:00
MHDA- 2002/06/06 10:01
CRDT- 2002/05/16 10:00
PHST- 2002/05/16 10:00 [pubmed]
PHST- 2002/06/06 10:01 [medline]
PHST- 2002/05/16 10:00 [entrez]
AID - 10.1200/JCO.2002.08.155 [doi]
PST - ppublish
SO  - J Clin Oncol. 2002 May 15;20(10):2480-5. doi: 10.1200/JCO.2002.08.155.